Another-1 Immortalizes Street Art and Streetwear with ‘Drip-Lab’ - combining NFTs, PFPs and NFC Technology
20.7.2023 15:00:00 EEST | Business Wire | Press release
Another-1, the web3 luxury fashion platform, today announces the global launch of Drip-Lab – a multi-faceted phygital NFT project in collaboration with Como-based luxury technical fabric mill Olmetex, and renowned graffiti writer and artist Zoow24.
Drip-Lab launches with a mission to define the global intersection of art, graffiti, technology and streetwear, uniting a new and vibrant community of collectors and connoisseurs in the process. By launching a graffiti and street-culture inspired NFT collection, immortalizing Zoow24’s “The Wall” mural as an NFT, as well as linking the artist’s iconic illustrated characters to an NFC-enabled Olmetex fabricated windbreaker jacket, every aspect of the Drip-Lab project combines to ensure that historically ephemeral street art can be recorded, owned and flexed forever.
At the heart of this project are Zoow24’s five instantly recognisable ‘miniature behemoth’ monster character NFTs - REKT, EXTO, KULT, CRYMELON, and ROOT - which represent vices that can cause an artist to lose their way. The NFTs will be available with over 1,700 backgrounds, 183 monster traits, and 5,555 profile pictures (PFPs) variations as the Drip-Lab community grows.
In short, this unique blend of physical and digital (phygital) utility offers ‘Drip-Lab’ holders around the world the chance to flex a range of digital PFPs, physical products and murals, as well as augmented reality experiences that will be revealed with Another-1’s plans for future activations.
The ‘Drip-Lab’ Roadmap
The Pre-mint for ‘Drip-Lab’ is now live in anticipation of the sale on the Another-1 ADO Launchpad, allowing interested community members exclusive access to mint this project by linking their wallet ahead of the public offering.
Next week, on Wednesday, July 26th at 1pm EDT / 5pm UTC, presale for the project opens, and on July 27th at 1pm EDT / 5pm UTC the public sale will go live. An individual PFP will cost $150 USD each and to forge a customized jacket will cost $350 USD. After the drop, added benefits and utilities will be revealed as holders of these PFP project NFTs will benefit from a free airdrop of an NFT that immortalizes ‘The Wall’ art created by Zoow24 in Como. Adding the fashion and streetwear element, a highly anticipated aspect of this project is a limited edition windbreaker jacket that comes equipped with Near Field Communication (NFC) technology.
Designed by Olmetex, a world-renowned Italian mill setting the standard for fashion’s leading technical fabrics, these jackets showcase five captivating thermo-reactive dual-colorways and feature ZOOW24’s monsters on the inside lining for a customized finish.
Apart from making sure its wearer looks good in the streets, ‘The Writer’s Jacket’ will enable its owners’ to take advantage of Another-1’s ‘Flex-To-Earn’ module and get a 25% cash back airdrop in $AN1 tokens once the collection sales have been concluded, and the NFT redeem for the physical Jacket will be available later this year.
Speaking on the project, artist Zoow24 said, “Drip-Lab is a cautionary expose of what vices become when they spiral out of control. When you stop doing the drugs and the drugs do you. Habits are what make us human and how we choose to spend our time defines us as people.” “As a whole, this collaboration with Another-1 and Olmetex has created an opportunity for me to take my art, my characters and my creativity to a whole range of platforms and possibilities.”
Marco Staglianò, CEO of Another-1, added, “Our mission is to push the envelope and radically change the way art is produced and traded. By establishing the Drip-Lab project along with Olmetex and renowned artists such as Zoow24, we are proving that graffiti is a medium that can live on and be appreciated forever. This is a historical crossover of art, fashion, and groundbreaking technology and we’re excited for what’s still to come.”
“Working with a renowned fabric manufacturer like Olmetex, we also have the opportunity to tie physical fashion to this story of street and digital art. This is a first for the world and we’re excited to see how these passionate communities of street art and streetwear collectors will respond.”
Finally, Olmetex Managing Director, Beatrice Breschi had this to say: “Olmetex has decided to make the facade of its textile company available to graffiti artists, because it has always believed in the close union between fashion and art. This approach is a source of inspiration for our customers, which has always been part of our spirit and characteristics: elasticity, flexibility and constant openness to new ideas and challenges that the market offers. With these NFTs and the physical redemption of the waterproof jacket produced with its own fabrics, Olmetex sets itself the goal of making an art project tangible and fashionable.
“We’re excited to see our near-70 year old Mill involved in a web3 project that creates a new and important way to enjoy art and fashion. We have always been future-focused with our fabric innovation, and now we are taking this mindset to a collaboration that takes fashion, art and fabric into the next decade.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720752001/en/
Contact information
Bridget van Voorst
bridget@cw8-communications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
